Press Releases Year None202620252024202320222021 August 6, 2026 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 5, 2026 NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results July 29, 2026 NewAmsterdam Pharma to Host Investor Day on August 5, 2026 July 24, 2026 NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) July 2, 2026 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 1, 2026 NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 June 3, 2026 NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions May 28, 2026 NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June May 11, 2026 NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May May 7, 2026 NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 21
August 5, 2026 NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
July 24, 2026 NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
July 1, 2026 NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
June 3, 2026 NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
May 7, 2026 NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
